November 17 FDA Meeting Puts NEO212’s Next Development Stage in Focus
DENVER, Colo. (247marketnews.com)– NeOnc Technologies Holdings (NASDAQ:NTHI) is approaching a potentially important regulatory checkpoint as the company prepares for a November 17, 2026, in-person End-of-Phase 1 Type B meeting with the U.S. Food and Drug Administration regarding NEO212, its investigational oral perillyl alcohol-temozolomide conjugate being developed for difficult-to-treat central nervous system cancers. The meeting comes as NeOnc advances two clinical programs and builds a development pipeline increasingly centered on potential late-stage opportunities in brain cancer.
At the November meeting, NeOnc plans to seek FDA feedback on the proposed patient population for NEO212, Phase 2 study design, endpoints, dose selection and the evidence that could potentially support a future marketing application. The company also intends to discuss a potential registrational strategy and whether a future Phase 2 study could potentially provide a path toward accelerated approval.
NEO212 enters the regulatory discussion with a completed Phase 1 dose-escalation study and a recommended Phase 2 dose of 610 mg, following escalation to a protocol-defined maximum tolerated dose of 810 mg. The company eported several individual patient observations that it believes warrant further investigation. One patient with recurrent IDH1 wild-type, MGMT-methylated glioblastoma experienced approximately 60% tumor reduction and 21 months of disease control, while another heavily pretreated patient with lung cancer metastatic to the brain experienced stable disease for approximately 16 months.
NeOnc CEO Amir Heshmatpour has described the purpose of the upcoming regulatory discussion directly: “This meeting will help us understand FDA’s feedback on the population, study design and endpoints for the next stage of development.” The company has also received authorization for a UAE IND for NEO212, providing an additional international clinical-development avenue. Earlier FDA feedback on the program included discussions around chemistry, manufacturing and controls as well as the planned transition from a capsule formulation to a tablet, adding another layer to the development work ahead.
The NEO212 story is developing alongside new clinical data from NeOnc’s lead asset, NEO100, which is being evaluated in recurrent or progressive Grade III and Grade IV IDH1-mutant glioma. In August, the company reported topline Phase 2a results showing 48.9% six-month progression-free survival, compared with a prespecified 20% benchmark, with a reported p-value of 0.0047. Median overall survival was reported at 26.09 months, while 86.7% of patients were alive at six months. NeOnc said five of 24 patients remained on treatment at the data cutoff and that one partial response was continuing beyond 114 days. The company plans to engage with the FDA regarding a potential registrational development pathway for NEO100.
That creates two distinct clinical narratives inside the same company. NEO100 is moving forward on the basis of Phase 2a data and potential regulatory discussions, while NEO212 is approaching the FDA with a completed Phase 1 program, a defined recommended Phase 2 dose and a proposed next-stage development strategy. If both programs continue advancing, NeOnc could have multiple regulatory and clinical milestones to monitor into 2027 rather than relying on a single pipeline asset.
NeOnc has also strengthened its balance sheet as those development programs move forward. In September, the company completed a $15 million registered direct offering at $4.20 per share, accompanied by warrants carrying a $4.20 exercise price. The financing included healthcare-focused institutional investors, with proceeds earmarked for working capital, general corporate purposes and the redemption of the company’s Series A convertible preferred stock. NeOnc subsequently announced the redemption of all 6,000 outstanding Series A preferred shares for $6 million in cash, stating that the transaction eliminated the associated potential dilution without issuing common shares in the redemption.
Insider buying has added another notable data point. NeOnc reported approximately $629,000 in open-market purchases by company executives following the NEO100 Phase 2a results. CEO Amir Heshmatpour, for example, purchased an additional 35,000 shares for approximately $115,400, according to the company’s disclosure.
Wall Street has also begun paying closer attention to the developing pipeline. Roth Capital initiated coverage of NeOnc in September with a reported $20 price target, while analyst Jonathan Aschoff identified potential pivotal development milestones for both NEO100 and NEO212.
For NeOnc, the calendar is now increasingly defined by clinical and regulatory milestones: the November 17 FDA meeting for NEO212, continued development of NEO100 following its Phase 2a readout, potential FDA discussions regarding a registrational pathway, international development activity and execution of the company’s recently strengthened financing position.
About 24/7 Market News
In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
Editor@247mnn.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.